Thermo Fisher Highlights Diagnostics at ADLM 2026

Thermo Fisher Scientific, will showcase its latest diagnostic innovations, recent regulatory milestones and expanded capabilities at the Association for Diagnostics & Laboratory Medicine Conference (ADLM), July 26-30, 2026, in Anaheim, Calif. Spanning specialty diagnostics, quality management and the full diagnostic continuum, Thermo Fisher’s presence at ADLM 2026 reflects its ongoing commitment to addressing unmet clinical needs with reliable, purpose-built diagnostic and workflow solutions.

“Laboratories today face growing pressure to deliver faster, more accurate results while managing operational complexity,” said Puneet Sarin, senior vice president and president, specialty diagnostics at Thermo Fisher. “At the same time, the traditional boundaries between research, translational medicine and diagnostics continue to blur as science advances and healthcare evolves. With the breadth of our diagnostics portfolio—including instruments, assays and digital solutions—Thermo Fisher is uniquely positioned to help laboratories accelerate innovation, enable precision medicine and deliver the reliable insights clinicians need to improve patient care.”

Innovation to Address Unmet Clinical Needs

Thermo Fisher’s EXENT® Solution, a fully integrated and automated mass spectrometry platform designed to aid in the diagnosis of multiple myeloma and related disorders, recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA).  According to the International Myeloma Foundation (IMF), more than 176,000 people worldwide are diagnosed with multiple myeloma each year, yet the current diagnostic pathway can be slow and uncertain, often relying on subjective interpretation of test results. By combining increased sensitivity with automated workflows, the EXENT System helps clinical laboratories deliver accurate results, supporting fast, confident diagnoses and more informed clinical decision-making. The system is currently available for clinical use in Australia, Belgium, Brazil, Canada, France, Germany, Italy, the Netherlands, New Zealand, Spain, Switzerland, the United Kingdom and the United States.

In oncology, the Oncomine™ Dx Express Test (ODxET) on the Ion Torrent™ Genexus™ Dx Integrated Sequencer received FDA approval in 2025 as a companion diagnostic for sunvozertinib (Zegfrovy) in non–small cell lung cancer and for tumor profiling in FFPE samples. The system, in conjunction with ODxET, enables rapid next-generation sequencing (NGS) results in as little as 24 hours, helping care teams act on genomic information without adding days to an already difficult wait.*

In autoimmune disease diagnostics, Thermo Fisher’s EliA™ CTD 13 Screen received U.S. Food and Drug Administration (FDA) 510(k) clearance in June 2026, providing clinical laboratories with a new option for systemic connective tissue disease (CTD) testing. As physicians and laboratories work to evaluate patients with complex autoimmune conditions, the assay helps streamline testing workflows with results that support targeted follow-up testing and informed clinical decision-making. Available on the Phadia™ 250 instrument, EliA CTD 13 Screen is intended to aid in the diagnosis of systemic autoimmune connective tissue diseases, including systemic lupus erythematosus, Sjögren’s syndrome, systemic sclerosis, polymyositis, dermatomyositis and mixed connective tissue disease, when used in conjunction with other laboratory and clinical findings.

Thermo Fisher will also feature its B·R·A·H·M·S™ biomarker testing portfolio, which improves early diagnosis and informs treatment plans for life-threatening illnesses, such as sepsis and preeclampsia. Anchored by the Thermo Scientific B·R·A·H·M·S KRYPTOR Analyzers, the portfolio includes procalcitonin (PCT) testing for antibiotic stewardship in sepsis management, and the PreClara Ratio™**, which is the first FDA-cleared biomarker test for preeclampsia risk assessment, offering clarity on a condition that remains a leading cause of maternal and neonatal morbidity worldwide.

Thermo Fisher’s transplant diagnostics offerings, covering HLA typing and post-transplant monitoring patients, enhance a specialty diagnostics portfolio that spans from rare blood cancers and preeclampsia to autoimmune disease and transplant medicine. Each innovative solution was designed to improve diagnostic precision and patient care where standard approaches have left critical clinical questions unanswered. 

Advancing Diagnostics Through Deeper Research Insights & Digital Tools

The Thermo Scientific™ TSQ Certis™ Triple Quadrupole Mass Spectrometer***, launched in late 2025, brings high sensitivity and robustness to clinical research workflows including immunosuppressant drug monitoring, toxicology and bioanalysis. Designed for regulated environments, the TSQ Certis supports the analytical rigor that translates research-stage biomarkers into clinical insights. Also on display, the Applied Biosystems™ QuantStudio™ Dx Real-Time PCR System supports molecular diagnostics workflows in clinical and public health laboratories, offering a scalable platform for infectious disease testing and pathogen detection.

Across its diagnostics portfolio, Thermo Fisher continues to introduce digital innovations that help laboratories improve workflow efficiency and support standardized clinical decision-making. A recent addition is Thermo Scientific B·R·A·H·M·S Fast Screen™ PLUS, which completes the company's prenatal screening solution by integrating biomarkers, instrumentation and clinically validated risk assessment algorithms into a connected digital platform designed to support standardized interpretation, consistent reporting and streamlined prenatal screening workflows. 

Quality Management Is a Clinical Imperative 

Reliable results begin with robust quality controls. At ADLM, Thermo Fisher will showcase two complementary solutions that advance quality management beyond routine compliance. The LabLink360™ features Sigma-metric analysis, a global benchmarking tool that enables labs to assess performance and optimize quality control (QC) parameters so that they can identify opportunities to reduce QC burden without compromising performance. Paired with Thermo Scientific MAS™ Max quality controls, streamlined and automated workflows enable lab technicians to focus more on delivering fast and accurate patient results.

Supporting Labs from Development Through Delivery

Beyond its clinical diagnostics portfolio, Thermo Fisher serves as a trusted, end-to-end partner to in vitro diagnostic (IVD) companies through its Diagnostic Services business, offering contract manufacturing, regulatory compliance support and co-development capabilities across major testing disciplines. Regionalization, evolving regulatory requirements and platform consolidation are reshaping diagnostics platforms. The company’s global manufacturing footprint and deep technical expertise support the advancement of reliable diagnostic performance at a sustained scale.

This article has been republished from external sources. Note: Material may have been edited for clarity, length, or style. For more information, please contact the cited source.